|Bid||10.44 x 300|
|Ask||15.25 x 500|
|Day's Range||11.71 - 12.20|
|52 Week Range||8.80 - 16.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Summit Therapeutics Plc reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Summit Therapeutics Plc – Arena Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Acer Therapeutics Inc. and Aviragen Therapeutics Inc (ARNA-US, SRPT-US, ACER-US and AVIR-US) that have also reported for this ... Read more (Read more...)
Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.
Categories: Yahoo FinanceGet free summary analysis Summit Therapeutics Plc reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Summit Therapeutics Plc – Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc. and Proteon Therapeutics, Inc. (IONS-US, SRPT-US and PRTO-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)
Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy
Summit Therapeutics (SMMT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.
GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.